Skip to main content
No. of Recommendations: 3
Yes, positive result of study 901 will be a huge boost to NBIX and if ran under the old matrix, elagolix should be way into phase III by now.

However, this management has NO respect from me.
1. Look at their track record with Indiplon
2. Look at how they handle study 702 - yes, it is a brand new recording system. But it seems to me that they have NO understanding about the "symptoms" of non-menstrual pain whatsoever and have no clue what it takes to run a successful trial. Any experienced team would NOT have made such mistake.

I would go deep on elagolix if it is in good hands such as BMRN; with NBIX, a touch down is a much more nervous bet.
Print the post  


What was Your Dumbest Investment?
Share it with us -- and learn from others' stories of flubs.
When Life Gives You Lemons
We all have had hardships and made poor decisions. The important thing is how we respond and grow. Read the story of a Fool who started from nothing, and looks to gain everything.
Contact Us
Contact Customer Service and other Fool departments here.
Work for Fools?
Winner of the Washingtonian great places to work, and Glassdoor #1 Company to Work For 2015! Have access to all of TMF's online and email products for FREE, and be paid for your contributions to TMF! Click the link and start your Fool career.